Clinical Trials

Inclusion Criteria:

- Diagnosis of HS for at least 6 months prior to Baseline, as determined by the
investigator (i.e., through medical history and interview of subject).

- Documented history of previous use of ≥ 1 TNF inhibitor for HS for at least 12 weeks
and/or 1 approved non-anti-TNF biologic therapy for HS for at least 16 weeks
characterized by inadequate response or for any duration characterized by intolerance
as determined by the investigator.

- Participant must have a total AN count of ≥ 5 at Baseline.

- HS lesions must be present in at least 2 distinct anatomic areas at Baseline.

- At least 1 anatomic area of HS involvement characterized as Hurley Stage II or higher
at Baseline.

- Draining fistula count of ≤ 20 at Baseline.

Exclusion Criteria:

- History of active skin disease other than HS that could interfere with the assessment
of HS, including skin infections (bacterial, fungal, or viral) requiring systemic
treatment within 4 weeks of the Baseline visit.

- Treatment with any investigational drug of chemical or biologic nature within a
minimum of 30 days or 5 half-lives (whichever is longer) prior to the first dose of
study drug or be currently enrolled in another interventional clinical study.
Investigational drugs are also prohibited during the study.

- Previous treatment with any cell-depleting therapies including but not limited to
anti-CD20 (e.g., rituximab) within 12 months prior to Baseline or until B cell count
returns to normal level or pre-treatment level.

- Use of prescription topical therapies (including topical antibiotics) that can also be
used to treat HS within 14 days prior to the Baseline visit.

- Received any systemic (including oral) antibiotic treatment for HS or any other
chronic inflammatory disorder within 14 days prior to the Baseline visit.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 9/5/23. Questions regarding updates should be directed to the study team contact.